ITEM VIEW

Perspectives of the management of childhood lymphoma: Experience at Tygerberg Hospital, Western Cape, South Africa

dc.contributor.authorWessels G.
dc.contributor.authorHesseling P.B.
dc.date.accessioned2011-05-15T16:18:16Z
dc.date.available2011-05-15T16:18:16Z
dc.date.issued2005
dc.identifier.citationTransfusion and Apheresis Science
dc.identifier.citation32
dc.identifier.citation1
dc.identifier.issn14730502
dc.identifier.other10.1016/j.transci.2004.10.003
dc.identifier.urihttp://hdl.handle.net/10019.1/14583
dc.description.abstractHodgkin's disease (HD) in children corresponds to a large degree to HD in adults. Non-Hodgkin's Lymphoma (NHL) in children, however, differs from NHL in adults with respect to the classification, natural history, management and course. For practical reasons clinicians generally classify and treat NHL in children as either B-cell or T-cell disease. Over the past 22 years, the Paediatric Oncology Unit of the Tygerberg Hospital has treated HD with three different regimens. Use of the CLVPP and MOPP/ABVD regimens resulted in late relapses that adversely affected event free survival (EFS). For the last four years HD has been treated according to the regimen suggested by Schellong with good short term survival rates. Lymphoblastic or T-cell NHL is treated with regimens normally used for acute lymphoblastic leukaemia (e.g. BFM protocols) or modified leukaemia treatments for leukaemia-lymphoma syndromes (e.g. LSA2L2). We lately use a modified BFM regimen with a 70% EFS for all stages. Three consecutive regimens have been used to treat B-cell NHL over the past 22 years. The first was a COMP regimen, followed by the LMB-89 and LMB-96 regimens. Although toxicity has increased with the increased intensity of the treatment regimen, EFS has improved from 25% to 87% for all B-cell NHL. The majority of patients had stage III and IV disease. Although the LMB regimens are toxic, the implementation is manageable provided good laboratory back up and supportive facilities are available. © 2005 Elsevier Ltd. All rights reserved.
dc.subjectantineoplastic agent
dc.subjectbleomycin
dc.subjectchlormethine
dc.subjectcyclophosphamide
dc.subjectdacarbazine
dc.subjectdoxorubicin
dc.subjectmethotrexate
dc.subjectprednisone
dc.subjectprocarbazine
dc.subjectvinblastine
dc.subjectvincristine
dc.subjectvincristine sulfate
dc.subjectacute lymphoblastic leukemia
dc.subjectage distribution
dc.subjectB cell lymphoma
dc.subjectcancer chemotherapy
dc.subjectcancer classification
dc.subjectcancer relapse
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectchildhood disease
dc.subjectconference paper
dc.subjectdisease course
dc.subjectdisease severity
dc.subjectHodgkin disease
dc.subjecthospital
dc.subjecthuman
dc.subjectlymphoblastoma
dc.subjectlymphoma
dc.subjectnonhodgkin lymphoma
dc.subjectphysician
dc.subjectside effect
dc.subjectSouth Africa
dc.subjectsurvival rate
dc.subjectT cell lymphoma
dc.subjecttreatment outcome
dc.subjectAdult
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectBleomycin
dc.subjectBlood Transfusion
dc.subjectChild
dc.subjectCombined Modality Therapy
dc.subjectDacarbazine
dc.subjectDisease-Free Survival
dc.subjectDoxorubicin
dc.subjectHodgkin Disease
dc.subjectHumans
dc.subjectLymphoma, Non-Hodgkin
dc.subjectMechlorethamine
dc.subjectPrednisone
dc.subjectProcarbazine
dc.subjectRecurrence
dc.subjectSouth Africa
dc.subjectTime Factors
dc.subjectVinblastine
dc.subjectVincristine
dc.titlePerspectives of the management of childhood lymphoma: Experience at Tygerberg Hospital, Western Cape, South Africa
dc.typeConference Paper
dc.description.versionConference Paper


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW